ADGRE5 and leukemia: By correlating these data to the relevant clinic-pathological parameters of the patients, CD97/ADGRE5 has been identified as a leukemia-associated candidate in acute myeloid (AML) [84], (pediatric) acute lymphoblastic [83,85], and chronic lymphocytic leukemia.